DK1272489T3 - Fremgangsmåde til præparation af cabergolins krystallinske form I - Google Patents

Fremgangsmåde til præparation af cabergolins krystallinske form I

Info

Publication number: DK1272489T3
Authority: DK; Denmark
Prior art keywords: cabergoline; preparation; crystalline form; crystalline
Prior art date: 2000-03-24

Application number

DK01936098T

Other languages

Danish (da)

English (en)

Inventor

Attilio Tomasi

Stefania Magenes

Mario Ungari

Giuliano Ramella

Gianfranco Pallanza

Original Assignee

Pharmacia Italia Spa

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2000-03-24

Filing date

2001-03-19

Publication date

2003-12-15

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=9888433&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1272489(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2001-03-19 Application filed by Pharmacia Italia Spa filed Critical Pharmacia Italia Spa

2003-12-15 Application granted granted Critical

2003-12-15 Publication of DK1272489T3 publication Critical patent/DK1272489T3/da

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
- C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
- C07D457/06—Lysergic acid amides
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
- C07D457/04—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 8
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/08—Bronchodilators
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/16—Masculine contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A61P27/06—Antiglaucoma agents or miotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid

Landscapes

Health & Medical Sciences (AREA)
Organic Chemistry (AREA)
Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Veterinary Medicine (AREA)
Medicinal Chemistry (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Life Sciences & Earth Sciences (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Chemical Kinetics & Catalysis (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Biomedical Technology (AREA)
Ophthalmology & Optometry (AREA)
Psychiatry (AREA)
Hospice & Palliative Care (AREA)
Diabetes (AREA)
Hematology (AREA)
Psychology (AREA)
Endocrinology (AREA)
Reproductive Health (AREA)
Pulmonology (AREA)
Nitrogen Condensed Heterocyclic Rings (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

DK01936098T 2000-03-24 2001-03-19 Fremgangsmåde til præparation af cabergolins krystallinske form I DK1272489T3 (da)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0007308.0A GB0007308D0 (en)	2000-03-24	2000-03-24	Process for preparing crystalline form \| of cabergoline
PCT/EP2001/003099 WO2001070740A1 (en)	2000-03-24	2001-03-19	Process for preparing crystalline form i of cabergoline

Publications (1)

Publication Number	Publication Date
DK1272489T3 true DK1272489T3 (da)	2003-12-15

Family

ID=9888433

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
DK01936098T DK1272489T3 (da)	2000-03-24	2001-03-19	Fremgangsmåde til præparation af cabergolins krystallinske form I

Country Status (31)

Country	Link
US (2)	US6727363B2 (de)
EP (1)	EP1272489B1 (de)
JP (1)	JP4184666B2 (de)
KR (1)	KR100827558B1 (de)
CN (1)	CN1188412C (de)
AR (1)	AR032449A1 (de)
AT (1)	ATE250601T1 (de)
AU (2)	AU780747B2 (de)
BR (1)	BR0109507A (de)
CA (1)	CA2402836A1 (de)
CZ (1)	CZ20023176A3 (de)
DE (1)	DE60100858T2 (de)
DK (1)	DK1272489T3 (de)
EA (1)	EA005928B1 (de)
EE (1)	EE05088B1 (de)
ES (1)	ES2208602T3 (de)
GB (1)	GB0007308D0 (de)
HK (1)	HK1052348B (de)
HU (1)	HUP0300591A3 (de)
IL (2)	IL150985A0 (de)
MX (1)	MXPA02009283A (de)
MY (1)	MY134189A (de)
NO (1)	NO20024321D0 (de)
NZ (1)	NZ521316A (de)
PE (1)	PE20011140A1 (de)
PL (1)	PL358253A1 (de)
PT (1)	PT1272489E (de)
SI (1)	SI1272489T1 (de)
SK (1)	SK13582002A3 (de)
WO (1)	WO2001070740A1 (de)
ZA (1)	ZA200206045B (de)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB0007307D0 (en) *	2000-03-24	2000-05-17	Pharmacia & Upjohn Spa	Crystalline form \|\| of cabergoline
GB0007308D0 (en) *	2000-03-24	2000-05-17	Pharmacia & Upjohn Spa	Process for preparing crystalline form \| of cabergoline
DE10043321B4 (de) *	2000-08-24	2005-07-28	Neurobiotec Gmbh	Verwendung eines transdermalen therapeutischen Systems zur Behandlung der Parkinsonschen Krankheit, zur Behandlung und Prävention des prämenstruellen Syndroms und zur Lactationshemmung
DE10053397A1 (de) *	2000-10-20	2002-05-02	Schering Ag	Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
DE10064453A1 (de) *	2000-12-16	2002-07-04	Schering Ag	Verwendung eines dopaminergen Wirkstoffes zur Behandlung von dopaminerg behandelbaren Erkrankungen
CA2478149A1 (en) *	2002-03-15	2003-09-25	Pharmacia Corporation	Process for preparing crystalline form i of cabergoline
EP1485383A1 (de) *	2002-03-15	2004-12-15	Pharmacia Corporation	Verfahren zum herstellen der kristallinen form i von cabergolin
IL155545A (en) *	2003-04-21	2009-12-24	Finetech Pharmaceutical Ltd	Solvate form of cabergoline
KR20060028761A (ko) *	2003-05-08	2006-04-03	아이박스 파마슈티컬스 에스.알.오.	다형의 카베르골린
GB0409785D0 (en) *	2004-04-30	2004-06-09	Resolution Chemicals Ltd	Preparation of cabergoline
GB0515430D0 (en) *	2005-07-27	2005-08-31	Resolution Chemicals Ltd	Preparation of cabergoline
GB0505965D0 (en)	2005-03-23	2005-04-27	Resolution Chemicals Ltd	Preparation of cabergoline
US7339060B2 (en)	2005-03-23	2008-03-04	Resolution Chemicals, Ltd.	Preparation of cabergoline
EP1925616A1 (de) *	2006-10-26	2008-05-28	LEK Pharmaceuticals D.D.	Verfahren zur Herstellung kristalliner Formen des Cabergolins via stabile Solvate des Cabergolins
EP1953157A1 (de)	2007-01-31	2008-08-06	LEK Pharmaceuticals D.D.	Neue Kristallform von Cabergolin
WO2009027086A2 (en) *	2007-08-29	2009-03-05	Max Zeller Söhne Ag	Use of vitex agnus castus extracts for preparing a medicament
EP4074552B1 (de) *	2021-04-16	2024-04-03	Thermo King LLC	Elektrische verbindungseinheit

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
DE3019322A1 (de)	1980-05-21	1981-12-03	Merck Patent Gmbh, 6100 Darmstadt	Psychopharmakon sowie verwendung von adenosinderivaten
US4526892A (en) *	1981-03-03	1985-07-02	Farmitalia Carlo Erba, S.P.A.	Dimethylaminoalkyl-3-(ergoline-8'βcarbonyl)-ureas
GB2103603B (en) *	1981-08-11	1985-04-11	Erba Farmitalia	Ergoline derivatives
GB9205439D0 (en)	1992-03-12	1992-04-22	Erba Carlo Spa	Process for the synthesis of ergoline derivatives
EP0664705B1 (de)	1993-08-18	2000-10-04	Alcon Laboratories, Inc.	Zusammensetzungen von ergolinderivaten zur behandlung des glaukoms
WO1999036095A1 (en)	1998-01-13	1999-07-22	Astrazeneca Uk Limited	PHARMACEUTICAL COMPOSITIONS COMPRISING A COMPOUND HAVING DOPAMINE (D2) RECEPTOR AGONIST ACTIVITY AND A COMPOUND (B) HAVING β2-ADRENORECEPTOR AGONIST ACTIVITY
PL343593A1 (en)	1998-03-27	2001-08-27	Upjohn Co	Use of cabergoline in the treatment of restless legs syndrome
GB0007308D0 (en)	2000-03-24	2000-05-17	Pharmacia & Upjohn Spa	Process for preparing crystalline form \| of cabergoline
GB0007309D0 (en)	2000-03-24	2000-05-17	Pharmacia & Upjohn Spa	Crystalline form V\|\| of cabergoline
GB0007307D0 (en)	2000-03-24	2000-05-17	Pharmacia & Upjohn Spa	Crystalline form \|\| of cabergoline

2000
- 2000-03-24 GB GBGB0007308.0A patent/GB0007308D0/en not_active Ceased
2001
- 2001-03-13 PE PE2001000237A patent/PE20011140A1/es not_active Application Discontinuation
- 2001-03-19 AU AU62110/01A patent/AU780747B2/en not_active Ceased
- 2001-03-19 AT AT01936098T patent/ATE250601T1/de not_active IP Right Cessation
- 2001-03-19 KR KR1020027012590A patent/KR100827558B1/ko not_active IP Right Cessation
- 2001-03-19 PT PT01936098T patent/PT1272489E/pt unknown
- 2001-03-19 CN CNB018070051A patent/CN1188412C/zh not_active Expired - Fee Related
- 2001-03-19 PL PL01358253A patent/PL358253A1/xx not_active Application Discontinuation
- 2001-03-19 EP EP01936098A patent/EP1272489B1/de not_active Expired - Lifetime
- 2001-03-19 JP JP2001568941A patent/JP4184666B2/ja not_active Expired - Fee Related
- 2001-03-19 ES ES01936098T patent/ES2208602T3/es not_active Expired - Lifetime
- 2001-03-19 BR BR0109507-2A patent/BR0109507A/pt not_active Application Discontinuation
- 2001-03-19 NZ NZ521316A patent/NZ521316A/en unknown
- 2001-03-19 SI SI200130045T patent/SI1272489T1/xx unknown
- 2001-03-19 DE DE60100858T patent/DE60100858T2/de not_active Expired - Fee Related
- 2001-03-19 EE EEP200200545A patent/EE05088B1/xx not_active IP Right Cessation
- 2001-03-19 IL IL15098501A patent/IL150985A0/xx active IP Right Grant
- 2001-03-19 SK SK1358-2002A patent/SK13582002A3/sk unknown
- 2001-03-19 WO PCT/EP2001/003099 patent/WO2001070740A1/en active IP Right Grant
- 2001-03-19 CZ CZ20023176A patent/CZ20023176A3/cs unknown
- 2001-03-19 HU HU0300591A patent/HUP0300591A3/hu unknown
- 2001-03-19 MX MXPA02009283A patent/MXPA02009283A/es active IP Right Grant
- 2001-03-19 CA CA002402836A patent/CA2402836A1/en not_active Withdrawn
- 2001-03-19 US US10/239,636 patent/US6727363B2/en not_active Expired - Fee Related
- 2001-03-19 DK DK01936098T patent/DK1272489T3/da active
- 2001-03-19 AR ARP010101263A patent/AR032449A1/es unknown
- 2001-03-19 EA EA200201016A patent/EA005928B1/ru unknown
- 2001-03-22 MY MYPI20011364A patent/MY134189A/en unknown
2002
- 2002-07-29 ZA ZA200206045A patent/ZA200206045B/xx unknown
- 2002-07-30 IL IL150985A patent/IL150985A/en not_active IP Right Cessation
- 2002-09-10 NO NO20024321A patent/NO20024321D0/no not_active Application Discontinuation
2003
- 2003-06-25 HK HK03104554.7A patent/HK1052348B/zh not_active IP Right Cessation
- 2003-10-31 US US10/698,737 patent/US6953854B2/en not_active Expired - Fee Related
2005
- 2005-07-14 AU AU2005203071A patent/AU2005203071B2/en not_active Ceased

Also Published As

Publication number	Publication date
ATE250601T1 (de)	2003-10-15
DE60100858D1 (de)	2003-10-30
EE200200545A (et)	2004-04-15
PT1272489E (pt)	2004-02-27
HUP0300591A2 (hu)	2003-07-28
CN1419554A (zh)	2003-05-21
EP1272489A1 (de)	2003-01-08
MY134189A (en)	2007-11-30
US6727363B2 (en)	2004-04-27
PL358253A1 (en)	2004-08-09
AU6211001A (en)	2001-10-03
HK1052348B (zh)	2005-09-16
ES2208602T3 (es)	2004-06-16
KR100827558B1 (ko)	2008-05-07
EA005928B1 (ru)	2005-08-25
WO2001070740A1 (en)	2001-09-27
AU2005203071A1 (en)	2005-08-11
CZ20023176A3 (cs)	2003-02-12
IL150985A (en)	2007-03-08
AU2005203071B2 (en)	2007-10-18
AU780747B2 (en)	2005-04-14
NO20024321L (no)	2002-09-10
PE20011140A1 (es)	2001-11-01
US20030149067A1 (en)	2003-08-07
HUP0300591A3 (en)	2009-01-28
IL150985A0 (en)	2003-02-12
US6953854B2 (en)	2005-10-11
SK13582002A3 (sk)	2003-04-01
DE60100858T2 (de)	2004-07-29
EE05088B1 (et)	2008-10-15
EP1272489B1 (de)	2003-09-24
JP4184666B2 (ja)	2008-11-19
NZ521316A (en)	2004-05-28
CN1188412C (zh)	2005-02-09
US20040092744A1 (en)	2004-05-13
GB0007308D0 (en)	2000-05-17
SI1272489T1 (en)	2004-02-29
KR20020081587A (ko)	2002-10-28
JP2003528100A (ja)	2003-09-24
NO20024321D0 (no)	2002-09-10
EA200201016A1 (ru)	2003-02-27
BR0109507A (pt)	2002-12-10
CA2402836A1 (en)	2001-09-27
MXPA02009283A (es)	2003-03-12
AR032449A1 (es)	2003-11-12
HK1052348A1 (en)	2003-09-11
ZA200206045B (en)	2003-07-29

Publication	Publication Date	Title
DK1296935T3 (da)	2009-06-22	Fremgangsmåde til fremstilling af substituerede octanoylamider
DK1296656T3 (da)	2006-11-27	Fremgangsmåde til fremstilling af et præparat
DK1303478T3 (da)	2004-08-30	Fremgangsmåde til fremstilling af substituerede octanoylamider
DK1173431T3 (da)	2003-08-04	Fremgangsmåde til fremstilling af citalopram
DK1105382T3 (da)	2002-05-27	Fremgangsmåde til fremstilling af citalopram
DK1293507T3 (da)	2007-12-27	Fremgangsmåde til fremstilling af krystaller
DK1159274T3 (da)	2003-07-21	Fremgangsmåde til fremstilling af citalopram
DK1309545T3 (da)	2007-10-29	Fremgangsmåde til fremstilling af alkylarylsulfonater
DK1181272T3 (da)	2002-12-30	Fremgangsmåde til fremstilling af rent citalopram
DK1181713T3 (da)	2005-01-31	Fremgangsmåde til fremstilling af rent citalopram
DK1309582T3 (da)	2005-03-14	Fremgangsmåde til fremstilling af citalopram
DK1272489T3 (da)	2003-12-15	Fremgangsmåde til præparation af cabergolins krystallinske form I
DK1345939T3 (da)	2006-09-25	Fremgangsmåde til fremstilling af sulfonamidsubstituerede imidazotriazinoner
DK1280803T3 (da)	2005-01-24	Krystallinsk form II af cabergolin
DK1187833T3 (da)	2007-10-08	Fremgangsmåde til fremstilling af thiamethoxam
DK1326836T3 (da)	2004-06-01	Fremgangsmåde til fremstilling af 3-amino-2-chlor-4-methylpyridin
DK1456229T3 (da)	2010-01-04	Fremgangsmåe til fremstilling af echinocandin-derivater
DK1296970T3 (da)	2008-07-14	Fremgangsmåde til fremstilling af citalopram
DK1292586T3 (da)	2004-08-30	Fremgangsmåde til fremstilling af pyrazolopyrimidinoner
DK1228056T3 (da)	2005-01-24	Fremgangsmåde til fremstilling af citalopram
DK1203000T3 (da)	2003-06-02	Fremgangsmåde til fremstilling af phosphonomethylglycin
DK1511724T3 (da)	2014-06-16	Fremgangsmåde til fremstilling af thioalkylaminderivater
DK1294694T3 (da)	2004-12-27	Fremgangsmåde til fremstilling af quinolinderivater
DK1240173T3 (da)	2003-09-15	Fremgangsmåde til fremstilling af N-phosphonomethylglycin
NO20030515D0 (no)	2003-02-03	Fremgangsmåte for fremstilling av dinapsolin